Skip to main content
Article
Individual and composite study endpoints: separating the wheat from the chaff
UMass Center for Clinical and Translational Science Supported Publications
  • Robert J. Goldberg, University of Massachusetts Medical School
  • Joel M. Gore, University of Massachusetts Medical School
  • Bruce A. Barton, University of Massachusetts Medical School
  • Jerry H. Gurwitz, University of Massachusetts Medical School
UMMS Affiliation
Department of Quantitative Health Sciences; Meyers Primary Care Institute; Department of Medicine, Division of Cardiovascular Medicine
Date
5-1-2014
Document Type
Article
Medical Subject Headings
*Clinical Trials as Topic; Cost-Benefit Analysis; *Endpoint Determination; Humans; *Outcome Assessment (Health Care); Prospective Studies; *Research Design; Sample Size; Treatment Outcome
Abstract
We provide an overview of the individual and combined clinical endpoints and patient-reported outcomes typically used in clinical trials and prospective epidemiological investigations. We discuss the strengths and limitations associated with the utilization of aggregated study endpoints and surrogate measures of important clinical endpoints and patient-centered outcomes. We hope that the points raised in this overview will lead to the collection of clinically rich, relevant, measurable, and cost-efficient study outcomes.
Comments

Citation: Goldberg R, Gore JM, Barton B, Gurwitz J. Individual and composite study endpoints: separating the wheat from the chaff. Am J Med. 2014 May;127(5):379-84. doi: 10.1016/j.amjmed.2014.01.011.

Related Resources
Link to Article in PubMed
Keywords
  • UMCCTS funding
PubMed ID
24486289
Citation Information
Robert J. Goldberg, Joel M. Gore, Bruce A. Barton and Jerry H. Gurwitz. "Individual and composite study endpoints: separating the wheat from the chaff" Vol. 127 Iss. 5 (2014) ISSN: 0002-9343 (Linking)
Available at: http://works.bepress.com/robert_goldberg/392/